Risks of Concomitant Statin Therapy with Gemfibrozil
Customize your policy alerts
Sign up for all centralcaliforniaallianceforhealth policy alerts
Know when centralcaliforniaallianceforhealth releases new policies or updates existing guidance.
Monitor payer policy activity
Guidance on risks and management when statins are used with gemfibrozil, and preferred alternatives; intended for clinicians prescribing lipid-lowering therapy.
No material clinical or coverage changes in this revision.
Coverage Guidance
Coverage criterion: The policy advises that the combination of lovastatin, pravastatin, or simvastatin with gemfibrozil is not advised. This exclusion reflects documented drug–drug interaction concerns and the recommendation against these specific statin–gemfibrozil combinations.
Provider Actions and Prescribing Guidance
Not a prior‑authorization policy
This document is clinical guidance from the Medi‑Cal DUR program and is not an official payer prior authorization policy; it does not establish explicit prior authorization requirements or denial criteria.
Prior authorization: none specified in this guidance
No explicit prior authorization requirements are specified in this guidance; the document lists agents available on the Medi‑Cal Rx Contract Drugs List but does not state authorization rules or criteria.
- Table 1 lists atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, fenofibrate (including micronized), fenofibric acid, and gemfibrozil on the Medi‑Cal Rx Contract Drugs List.
Step‑therapy: recommendations, not a formal algorithm
The guidance does not provide a formal step‑therapy algorithm; it recommends a preferred fibrate (fenofibrate) over gemfibrozil and suggests alternative statins if fenofibrate is not tolerated.
- Prefer fenofibrate over gemfibrozil due to lower risk of muscle‑related toxicity when combined with statins.
- If fenofibrate is not tolerated, consider atorvastatin or rosuvastatin in combination with gemfibrozil as lower‑interaction alternatives.
Document clinical rationale when continuing a statin with gemfibrozil
If a clinician elects to continue a statin in a patient taking gemfibrozil, document the clinical rationale and consider alternative agents; use the ACC Statin Intolerance Tool for screening and management guidance.
- Document why combination therapy is warranted and any assessment of statin‑associated muscle symptoms (SAMS) or rhabdomyolysis risk.
- Consider switching to fenofibrate or, if fenofibrate is not tolerated, choosing atorvastatin or rosuvastatin as lower‑interaction options.
Continuation / Alternatives for Ongoing Therapy
Alternatives for patients taking statins and gemfibrozil
Covered when ALL of the following are met:
Referenced preferred fibrate alternative
Second-line statin options when fenofibrate intolerance occurs
Statin-fibrate combinations that are not advised
Step Therapy Considerations
| Step | Condition / trigger | Recommended action |
|---|---|---|
| 1 | Intolerance to fenofibrate | Consider atorvastatin or rosuvastatin in combination with gemfibrozil as lower‑interaction alternatives |
Background and Safety Concerns
Concomitant use of gemfibrozil with statins is associated with a clinically significant drug–drug interaction that can increase the risk of statin‑associated muscle symptoms (SAMS), including rare but serious rhabdomyolysis. This interaction has been described in case reports and identified in the FDA Adverse Event Reporting System; product prescribing information for all statins advises against concomitant use with gemfibrozil, and major guideline statements note the interaction.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.